IDEXX Laboratories (NASDAQ: IDXX) director gains 257 shares from RSU vesting

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Director Daniel M. Junius of IDEXX Laboratories reported a routine equity compensation event. On May 7, 2026, a grant of 257 restricted stock units vested, converting into 257 shares of common stock. After this vesting and conversion, he directly holds 3,561 shares of IDEXX common stock.

Insider Trade Summary

257 shares exercised/converted

Mixed 2 txns

Insider JUNIUS DANIEL M

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	257	$0.00	--
Exercise	Common Stock	257	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct, null); Common Stock — 3,561 shares (Direct, null)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock that vested in one installment on May 7, 2026. Not applicable.

Key Figures

RSUs vested: 257 units Shares acquired: 257 shares Holdings after transaction: 3,561 shares +1 more

4 metrics

RSUs vested 257 units Restricted stock units vesting on May 7, 2026

Shares acquired 257 shares Common stock received from RSU vesting

Holdings after transaction 3,561 shares Direct IDEXX common stock owned post-transaction

Exercise transactions 1 transaction, 257 shares Derivative exercise/conversion summary

Key Terms

Restricted Stock Unit, derivative security, contingent right, vesting

4 terms

Restricted Stock Unit financial

"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

contingent right financial

"represents a contingent right to receive one share of Issuer common stock"

vesting financial

"that vested in one installment on May 7, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

05/11/2026 - 05:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JUNIUS DANIEL M

(Last)

(First)

(Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK

MAINE

04092

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/07/2026		M		257	A	$0	3,561	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	05/07/2026		M			257	⁽¹⁾	⁽¹⁾	Common Stock	257	⁽²⁾	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock that vested in one installment on May 7, 2026.

2. Not applicable.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Daniel M. Junius	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did IDEXX Laboratories (IDXX) director Daniel M. Junius report?

Director Daniel M. Junius reported the vesting of 257 restricted stock units into 257 shares of IDEXX common stock. This was recorded as an exercise or conversion of a derivative security, reflecting routine equity compensation, not an open-market stock purchase or sale.

Was the IDEXX (IDXX) Form 4 transaction a stock sale or purchase?

The Form 4 does not show an open-market purchase or sale. Instead, it reports the exercise or conversion of 257 restricted stock units into common shares, a standard compensation-related event where units vest and become company stock without a market trade.

How many IDEXX (IDXX) shares did Daniel M. Junius acquire in this Form 4 filing?

He acquired 257 shares of IDEXX common stock through the vesting of 257 restricted stock units. Each unit represented a contingent right to receive one share that vested in a single installment on May 7, 2026, according to the filing footnote.

What are Daniel M. Junius’s IDEXX (IDXX) holdings after the reported transaction?

After the vesting and conversion, Daniel M. Junius directly holds 3,561 shares of IDEXX common stock. This figure reflects his direct ownership following the 257-share increase from restricted stock unit vesting disclosed in the Form 4 filing.

What does the restricted stock unit vesting mean for IDEXX (IDXX) shareholders?

The vesting of 257 restricted stock units into common shares is a routine equity compensation event. It modestly increases the director’s share count and slightly adds to outstanding shares, but the scale is small and does not represent a discretionary market trade.

How were the IDEXX (IDXX) restricted stock units described in the Form 4 footnotes?

The footnote states each restricted stock unit represented a contingent right to receive one share of IDEXX common stock. These units vested in a single installment on May 7, 2026, triggering their conversion into 257 common shares held directly by the director.